Thoracic TumoursPhase 1PEARNCT02587455
Pembrolizumab and Palliative Radiotherapy in Lung
A Phase 1 study testing Pembrolizumab and Radiotherapy in people with Thoracic Tumours, run by Royal Marsden NHS Foundation Trust at 2 sites in United Kingdom.
Trial summary
Lung cancer is the second most common cancer in the UK with around 43,500 new patients diagnosed each year. About 69% of patients are diagnosed with advanced stage disease and at present these patients would be expected to survive for less than 12 months. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thoracic Tumours
- What is being tested?
- Pembrolizumab and Radiotherapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 24 Jun 2016to 20 Aug 2021
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be willing and able to provide written informed consent for the trial.
- Have measurable disease based on RECIST 1.1.
- Histologically verified NSCLC including squamous cell carcinoma, adenocarcinoma, adenosquamous or large cell anaplastic carcinoma; requiring palliative radiotherapy for which no curative therapy exists will be recruited into the trial.
- Patients are permitted to have extrathoracic disease which will not be encompassed in the radiotherapy field. This disease will be assessed for abscopal response
- Ability to tolerate a course of palliative radiotherapy to the lung.
- Have provided tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumour lesion.
Show all 10Show fewer
- Have a performance status of 0-2 on the ECOG Performance Scale.
- Demonstrate adequate organ function, all screening labs should be performed within 10 days of confirmation of eligibility.
- Patient's lung function tests at baseline should have an FEV1 > 0.8L or > 30%.
- See protocol section.
Who cannot join
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- Previous radiotherapy to the lung
- Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
- Note: Patients with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
Show all 13Show fewer
- Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.
- Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require the use of bronchodilators or local steroid injections would not be excluded from the study. Patients with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.
- Has evidence of interstitial lung disease or active, noninfectious pneumonitis.
- Has received prior therapy with an antiPD1, antiPDL1, antiPDL2, antiCD137, or anti Cytotoxic T-lymphocyte associated antigen4 (CTLA4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
- See protocol section.
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)
London, SW3 6JJ
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)
Sutton, SM2 5PT
About this study
Official title: Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours
Lung cancer is the second most common cancer in the UK with around 43,500 new patients diagnosed each year. About 69% of patients are diagnosed with advanced stage disease and at present these patients would be expected to survive for less than 12 months. These statistics therefore show the need for the development of new effective drugs in the treatment of advanced Lung cancer.
Recent trial results have shown the efficacy of immunotherapy in treating several types of tumours including lung cancer. These tumours are known to express a high level of a glycoprotein called PDL1 which is a component of the PD1 pathway. In cancer the PD1 pathway can be hijacked by tumours leading to the immune system being suppressed. The aim of the new drug Pembrolizumab is to restart the PD1 pathway and use the immune system to help fight the cancer cells. Radiotherapy has also been shown to cause cancer to increase production of the proteins that can block the immune system. Therefore it has been proposed that combine of new immunotherapy agent such as pembrolizumab and radiotherapy in the treatment of lung cancer will allow more cancer cells to be killed through the immune system.
The purpose of this study is to see if pembrolizumab can safety be combined with standard palliative radiotherapy in patients with lung cancer. In addition once the patients have completed their course of radiotherapy they will remain on pembrolizumab alone and the study will look at how well this treatment regimen can control the growth of the cancer.
Read the detailed description
- Risk and burden for patients Patients in the first part of this study have cancer that is no longer responding to standard anticancer drug treatments.The phase 1 nature of this study means that the trial intervention may not have any additional benefit for patients who take part in the study. The study itself carries a number of potential burdens:
- Study drug and radiotherapy: Although the study drug safety effects have previously been assessed in NSCLC the side effects caused by the addition of radiotherapy is unconfirmed. These risks will be managed as much as possible by cautious dose escalation: as with all phase 1 studies, the data from each cohort will be reviewed by a safety review committee before deciding whether to increase the dose for subsequent cohorts. Participants will be reviewed regularly by experienced clinicians while having the study treatment. Comprehensive assessments for safety will be carried out.
- Burden of frequent hospital visits and tests: Participants in this study must attend hospital frequently, particularly at the start of the study, for safety reasons to check for any toxicity of the study treatment. Blood tests, clinical examination, urine tests, haematology, bio chemistry and lung function tests are part of the safety assessment. Additionally, for research purposes some participants may be asked to have additional blood taken, these will not be mandatory for entry into the study.
- Recruitment
Participants will be offered information about this study by their clinical teams if they are considered to meet the entry criteria (with regard to advanced disease without therapeutic option, suitable performance status) and express interest in taking part in an experimental study. It will be made clear that the study is experimental in nature and that there will not necessarily be a therapeutic benefit from taking part in the study. It will also be made clear that, should patients decide not to take part their future care will not be affected. Patients will be given sufficient time and information to make an informed decision about entering the trial, all patients entering the trial will give written informed consent.
- Confidentiality
Patients will be linked to a unique identifier the code for which will be held on a password protected database held only by the study team. This study will run at the Royal Marsden Hospital Only. Research blood and tumour data will be analysed by a team at the Institute of cancer Research. Sample processing will take place using the trial ID only. No other patient identifiable information will be available on study samples. Investigators will have access to patient identifiable information on password protected NHS hospital notes and databases only.
- Conflict of Interest
Patients may be recruited to the study by those involved in their prior clinical care. The investigators do not expect conflict of interest between research and healthcare duties for a number of reasons: patients must give their full informed consent before entering the study, specifically regarding the unknown efficacy of the study drug. Those patients who do not continue in the study will maintain a relationship with the clinical team if required for symptom control. At the end of the study, patients will be able to access the results if they wish, through the Royal Marsden Website. They will also be sent a written summary of the results if they indicate this.
- Use of tissue samples in future research
If participants give their consent, any leftover blood or tissue samples which are not required for this study will be stored for future unspecified research in line with the human tissue act regulations. Access and use of samples for research purposes will require appropriate ethical approval. Future researchers will not be able to identify individual patients from their biobank data, demographic and clinical information will be available.
- Conditions
- Thoracic Tumours
- Being tested
- Pembrolizumab, Radiotherapy
- Keywords
- Non-small cell carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PembrolizumabDrug
Also called MK-3475/pembrolizumab (KEYTRUDA®)
Pembrolizumab - Trial Treatment
RadiotherapyRadiation
Radiotherapy - Standard Treatment
| Study group | Role | What they receive |
|---|---|---|
| Low Dose Radiotherapy Arm | Experimental | Pembrolizumab and radiotherapy Receives: Drug: Pembrolizumab; Radiation: Radiotherapy |
| High Dose Radiotherapy Arm | Experimental | Pembrolizumab and radiotherapy Receives: Drug: Pembrolizumab; Radiation: Radiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4
DLT period is defined as the interval of 2 months following the final fraction of RT (at the beginning of cycle 4), using CTCAE v4.0 for acute toxicity. For this study a DLT would be regarded as any event of pneumonitis at ≥ grade 2.
DLTs were collected to determine the Maximum-Tolerated Dose (MTD). The toxicity rate will be stated as the proportion of patients who have had a DLT calculated with a 95% confidence interval.
Measured: 2 months following the final fraction of RT
Maximum Tolerated Dose (MTD) of Pembrolizumab That Can be Safely Combined With Radiotherapy (RT) in the Absence of Dose Limiting Toxicity (DLT) Assessed by CTCAEv4
MTD was determined by testing increasing doses of pembrolizumab (100mg / 200mg) and low/high doses of RT. MTD reflects the highest dose in the absence of a DLT. The DLT period is defined as the interval of 2 months following the final fraction of RT (at the beginning of cycle 4), using CTCAE v4.0 for acute toxicity. For this study a DLT would be regarded as any event of pneumonitis at ≥ grade 2.
Measured: 2 months following the final fraction of RT
Secondary outcomes (7)
Progression Free Survival at 6 and 12 Months
Progression-free survival (PFS) will be measured from the start of RT until radiological or clinical evidence of progression or else death from any cause. Any progression free surviving patients will be censored at last follow-up date. Using Kaplan-Meier methods, PFS rates at 6 months and 1 year will be reported with 95% confidence intervals.
Measured: 6 and 12 months
Overall Survival at 6 and 12 Months
Overall survival (OS) will be measured from the start of RT until death from any cause; any surviving patients will be censored at last follow-up date. Using Kaplan-Meier methods, survival rates at 6 months and 1 year will be reported with 95% confidence intervals.
Measured: 6 and 12 months
PFS at 6 and 12 Months by PDL-1 Status (Strong vs Non-strong)
PD-L1 staining is referred to as tumour proportion score, reported as a percentage from 0-100%. A PDL1 strong population will be those who have a tumour proportion score of >/=50%. Using Kaplan-Meier methods, survival rates at 6 months and 1 year for each PDL1 subgroup will be reported with 95% confidence intervals.
Measured: 6 and 12 months
OS at 6 and 12 Months by PDL-1 Status (Strong vs Non-strong)
PD-L1 staining is referred to as tumour proportion score, reported as a percentage from 0-100%. A PDL1 strong population will be those who have a tumour proportion score of >/=50%. Using Kaplan-Meier methods, survival rates at 6 months and 1 year for each PDL1 subgroup will be reported with 95% confidence intervals.
Measured: 6 and 12 months
Progression Free Survival (PFS2) From Date of First Response at 6 and 12 Months
Progression-free survival (PFS2) will be measured from the first response (defined as CR or PR or SD using RECIST v1.1) until radiological or clinical evidence of progression or else death from any cause (also known as "duration of clinical benefit"). Any patients not experiencing a response will not be included, and any progression free surviving patients will be censored at last follow-up date. Using Kaplan-Meier methods, PFS2 rates at 6 months and 1 year will be reported with 95% confidence intervals.
Measured: 6 and 12 months
PFS2 (From Date of First Response) by Histological Sub-types (Squamous vs Non-squamous)
Progression-free survival (PFS2) will be measured from the first response (defined as CR or PR or SD using RECIST v1.1) until radiological or clinical evidence of progression or else death from any cause (also known as "duration of clinical benefit"). Any patients not experiencing a response will not be included, and any progression free surviving patients will be censored at last follow-up date. Using Kaplan-Meier methods, PFS2 rates at 6 months and 1 year for each histological subgroup (squamous vs non-squamous) will be reported with 95% confidence intervals.
Measured: 6 and 12 months
Oesophagitis Rates Assessed at Two Months After the Last Fraction of RT Has Been Administered
Oesophagitis events will be determined by CTCAE v4.0. Proportion of patients with oesophagitis grade 2+ will be summarised with associated 95% confidence interval.
Measured: two months after the last fraction of RT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2015 (estimated)
- Study start24 Jun 2016
- Primary completion20 Aug 2021
- Study completion20 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Thoracic TumoursStudies of the same condition, open and under way.
- More trials run by Royal Marsden NHS Foundation TrustThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC, Institute of Cancer Research, United Kingdom, National Institute for Health Research, United Kingdom
- Responsible party
- Sponsor
- Investigators
- Dr Merina Ahmed, Study director, Consultant Clinical Oncologist
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02587455
- Sponsor's protocol ID
- CCR 4282
- Acronym
- PEAR
- Status last verified
- Apr 2026
- First submitted
- 13 Oct 2015
- Last updated
- 23 Apr 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours
- ClinicalTrials.gov ID
- NCT02587455
- Acronym / sponsor ID
- PEAR / CCR 4282
- Conditions
- Thoracic Tumours
- Keywords
- Non-small cell carcinoma
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Royal Marsden NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC, Institute of Cancer Research, United Kingdom, National Institute for Health Research, United Kingdom
- Study start
- 24 Jun 2016 (actual)
- Primary completion
- 20 Aug 2021 (actual)
- Study completion
- 20 Aug 2021 (actual)
- First posted
- 27 Oct 2015 (estimated)
- Results
- Posted 23 Apr 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung cancer is the second most common cancer in the UK with around 43,500 new patients diagnosed each year. About 69% of patients are diagnosed with advanced stage disease and at present these patients would be expected to survive for less than 12 months. These statistics therefore show the need for the development of new effective drugs in the treatment of advanced Lung cancer.
Recent trial results have shown the efficacy of immunotherapy in treating several types of tumours including lung cancer. These tumours are known to express a high level of a glycoprotein called PDL1 which is a component of the PD1 pathway. In cancer the PD1 pathway can be hijacked by tumours leading to the immune system being suppressed. The aim of the new drug Pembrolizumab is to restart the PD1 pathway and use the immune system to help fight the cancer cells. Radiotherapy has also been shown to cause cancer to increase production of the proteins that can block the immune system. Therefore it has been proposed that combine of new immunotherapy agent such as pembrolizumab and radiotherapy in the treatment of lung cancer will allow more cancer cells to be killed through the immune system.
The purpose of this study is to see if pembrolizumab can safety be combined with standard palliative radiotherapy in patients with lung cancer. In addition once the patients have completed their course of radiotherapy they will remain on pembrolizumab alone and the study will look at how well this treatment regimen can control the growth of the cancer.
Detailed description
- Risk and burden for patients Patients in the first part of this study have cancer that is no longer responding to standard anticancer drug treatments.The phase 1 nature of this study means that the trial intervention may not have any additional benefit for patients who take part in the study. The study itself carries a number of potential burdens:
- Study drug and radiotherapy: Although the study drug safety effects have previously been assessed in NSCLC the side effects caused by the addition of radiotherapy is unconfirmed. These risks will be managed as much as possible by cautious dose escalation: as with all phase 1 studies, the data from each cohort will be reviewed by a safety review committee before deciding whether to increase the dose for subsequent cohorts. Participants will be reviewed regularly by experienced clinicians while having the study treatment. Comprehensive assessments for safety will be carried out.
- Burden of frequent hospital visits and tests: Participants in this study must attend hospital frequently, particularly at the start of the study, for safety reasons to check for any toxicity of the study treatment. Blood tests, clinical examination, urine tests, haematology, bio chemistry and lung function tests are part of the safety assessment. Additionally, for research purposes some participants may be asked to have additional blood taken, these will not be mandatory for entry into the study.
- Recruitment
Participants will be offered information about this study by their clinical teams if they are considered to meet the entry criteria (with regard to advanced disease without therapeutic option, suitable performance status) and express interest in taking part in an experimental study. It will be made clear that the study is experimental in nature and that there will not necessarily be a therapeutic benefit from taking part in the study. It will also be made clear that, should patients decide not to take part their future care will not be affected. Patients will be given sufficient time and information to make an informed decision about entering the trial, all patients entering the trial will give written informed consent.
- Confidentiality
Patients will be linked to a unique identifier the code for which will be held on a password protected database held only by the study team. This study will run at the Royal Marsden Hospital Only. Research blood and tumour data will be analysed by a team at the Institute of cancer Research. Sample processing will take place using the trial ID only. No other patient identifiable information will be available on study samples. Investigators will have access to patient identifiable information on password protected NHS hospital notes and databases only.
- Conflict of Interest
Patients may be recruited to the study by those involved in their prior clinical care. The investigators do not expect conflict of interest between research and healthcare duties for a number of reasons: patients must give their full informed consent before entering the study, specifically regarding the unknown efficacy of the study drug. Those patients who do not continue in the study will maintain a relationship with the clinical team if required for symptom control. At the end of the study, patients will be able to access the results if they wish, through the Royal Marsden Website. They will also be sent a written summary of the results if they indicate this.
- Use of tissue samples in future research
If participants give their consent, any leftover blood or tissue samples which are not required for this study will be stored for future unspecified research in line with the human tissue act regulations. Access and use of samples for research purposes will require appropriate ethical approval. Future researchers will not be able to identify individual patients from their biobank data, demographic and clinical information will be available.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Low Dose Radiotherapy Arm | Experimental | Drug: Pembrolizumab, Radiation: RadiotherapyPembrolizumab and radiotherapy |
| High Dose Radiotherapy Arm | Experimental | Drug: Pembrolizumab, Radiation: RadiotherapyPembrolizumab and radiotherapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Be willing and able to provide written informed consent for the trial.
- Have measurable disease based on RECIST 1.1.
- Histologically verified NSCLC including squamous cell carcinoma, adenocarcinoma, adenosquamous or large cell anaplastic carcinoma; requiring palliative radiotherapy for which no curative therapy exists will be recruited into the trial.
- Patients are permitted to have extrathoracic disease which will not be encompassed in the radiotherapy field. This disease will be assessed for abscopal response
- Ability to tolerate a course of palliative radiotherapy to the lung.
Key exclusion criteria (13 listed)
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- Previous radiotherapy to the lung
- Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PembrolizumabAlso: MK-3475/pembrolizumab (KEYTRUDA®)Pembrolizumab - Trial Treatment | Drug | High Dose Radiotherapy Arm, Low Dose Radiotherapy Arm |
| RadiotherapyRadiotherapy - Standard Treatment | Radiation | High Dose Radiotherapy Arm, Low Dose Radiotherapy Arm |
Primary outcome
Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4
Time frame: 2 months following the final fraction of RT
DLT period is defined as the interval of 2 months following the final fraction of RT (at the beginning of cycle 4), using CTCAE v4.0 for acute toxicity. For this study a DLT would be regarded as any event of pneumonitis at ≥ grade 2. DLTs were collected to determine the Maximum-Tolerated Dose (MTD). The toxicity rate will be stated as the proportion of patients who have had a DLT calculated with a 95% confidence interval.
Maximum Tolerated Dose (MTD) of Pembrolizumab That Can be Safely Combined With Radiotherapy (RT) in the Absence of Dose Limiting Toxicity (DLT) Assessed by CTCAEv4
Time frame: 2 months following the final fraction of RT
MTD was determined by testing increasing doses of pembrolizumab (100mg / 200mg) and low/high doses of RT. MTD reflects the highest dose in the absence of a DLT. The DLT period is defined as the interval of 2 months following the final fraction of RT (at the beginning of cycle 4), using CTCAE v4.0 for acute toxicity. For this study a DLT would be regarded as any event of pneumonitis at ≥ grade 2.
7 secondary outcomes
Progression Free Survival at 6 and 12 Months
Time frame: 6 and 12 months
Overall Survival at 6 and 12 Months
Time frame: 6 and 12 months
PFS at 6 and 12 Months by PDL-1 Status (Strong vs Non-strong)
Time frame: 6 and 12 months
OS at 6 and 12 Months by PDL-1 Status (Strong vs Non-strong)
Time frame: 6 and 12 months
Progression Free Survival (PFS2) From Date of First Response at 6 and 12 Months
Time frame: 6 and 12 months
PFS2 (From Date of First Response) by Histological Sub-types (Squamous vs Non-squamous)
Time frame: 6 and 12 months
Oesophagitis Rates Assessed at Two Months After the Last Fraction of RT Has Been Administered
Time frame: two months after the last fraction of RT
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Thoracic Tumours
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr Merina Ahmed study director
Consultant Clinical Oncologist
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Pembrolizumab and Radiotherapy in people with Thoracic Tumours, run by Royal Marsden NHS Foundation Trust at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4 (time frame: 2 months following the final fraction of RT). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.